The Institute of Immunology of the Federal Medical and Biological Agency (FMBA) has submitted documents for registration of the drug for the Mir-19 coronavirus. This follows from the data of the register of medicines.
“Information related to the implementation of state registration. Trade name: Mir 19 “, – the document says.
Mir-19 is an inhalation drug that is inhaled using an inhaler through a mask.
At the end of December 2020, the head of the FMBA, Veronika Skvortsova, announced the development of an antidote for the Mir-19 coronavirus. The drug is based on the use of microRNAs that block certain sites of the RNA virus and those sites that are responsible for copying the virus molecule. It is safe for humans, does not affect the human genome and immunity, but at the same time effectively “turns off” the copying of the virus and prevents the most severe forms of coronavirus infection, the head of the FMBA said.
FMBA received a patent for this drug in April, information about it was published in the European journal Allergy.
.